Biopharmaceutical company Poolbeg Pharma (AIM: POLB) (OTCQB: POLBF) announced on Wednesday that it has been granted a Notice of Allowance from the US Patent Office for its Immunomodulator II patent application, enhancing its intellectual property portfolio. The notice signifies an impending formal grant of a patent.

The approved claims cover a class of drugs, including POLB 001, targeting hypercytokinaemia (cytokine storm) treatment and prevention post-immune response activation. POLB 001, a Phase II-ready p38 MAP kinase inhibitor, shows promise across various disease areas, particularly in severe influenza and cancer immunotherapies.

Poolbeg Pharma is actively expanding its patent portfolio, focusing on p38 MAP kinase inhibitors for severe influenza and POLB 001 for hypercytokinaemia treatment. Additional patent filings aim to broaden coverage, especially in cancer immunotherapies, boosting the appeal of POLB 001 to potential Pharma partners.

Committed to addressing diseases with high unmet medical needs, Poolbeg Pharma targets rare and orphan diseases. Led by a seasoned team, including former Amryt Pharma plc executives, Poolbeg aims to replicate past successes, driving value creation and near-term revenues.

The company's clinical programmes encompass cancer immunotherapy-induced CRS, infectious diseases, and metabolic conditions like obesity. Leveraging cost-effective development approaches and AI-led infectious disease programmes, Poolbeg accelerates drug development, offering greater commercial appeal and partnership opportunities.